[TNF alpha in the physiopathology of psoriasis]

Ann Dermatol Venereol. 2006 Feb;133(2):174-80. doi: 10.1016/s0151-9638(06)70873-0.
[Article in French]
No abstract available

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Chemokines / physiology
  • Cytokines / physiology
  • Dermatologic Agents / therapeutic use
  • Disease Models, Animal
  • Etanercept
  • Forecasting
  • Humans
  • Immunoglobulin G / therapeutic use
  • Infliximab
  • Keratinocytes / physiology
  • Lymphocyte Activation
  • Mice
  • Phenotype
  • Psoriasis / drug therapy
  • Psoriasis / genetics
  • Psoriasis / immunology
  • Psoriasis / pathology
  • Psoriasis / physiopathology*
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Receptors, Tumor Necrosis Factor, Type I / physiology
  • Receptors, Tumor Necrosis Factor, Type II / physiology
  • Research
  • Skin / pathology
  • Tumor Necrosis Factor-alpha / physiology*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Chemokines
  • Cytokines
  • Dermatologic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Receptors, Tumor Necrosis Factor, Type I
  • Receptors, Tumor Necrosis Factor, Type II
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept